Drugs / AIR DNase
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02605590 | Dec 2015 → Feb 2016 | cystic fibrosis | Protalix | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02722122 | May 2016 → Feb 2017 | cystic fibrosis | Protalix | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-06-12 | Protalix | Results Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis Conference protalix.com ↗
The mean viscosity reduction as a measure of activity on patients' sputa by AIR DNase is 70% compared to 30% for Pulmozyme. |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AIR-DNase | “single inhaled dose of 1.25 mg AIR-DNase followed by Part 2: once daily inhaled dose of 1.25 mg AIR DNase for 5 consecutive days.” NCT02605590 ↗ |
| Route | Inhaled | “administered by inhalation” NCT02605590 ↗ |